WASHINGTON, June 16 (Reuters) - U.S. regulators warned Matrixx Initiatives MTXX.O on Tuesday to stop selling zinc-containing, intranasal versions of its Zicam cold remedy after more than 130 reports of people losing their sense of smell.
The U.S. Food and Drug Administration also urged consumers to stop taking the over-the-counter products, agency officials said on a conference call with reporters.
Matrixx must seek FDA approval if it wants to continue selling the zinc-containing versions of Zicam that are administered through the nose, agency officials said. (Editing by Maureen Bavdek)
Our Standards: The Thomson Reuters Trust Principles.